HURA: TuHURA Biosciences Inc. Company Total Sales

Symbol and logo of brand TuHURA Biosciences Inc. (HURA)

The stability of TuHURA Biosciences, Inc. (HURA) is confirmed through an analysis of clinical phase risks and capital dynamics, where the company's sales level demonstrates the current trend and the parameter value reaches 0.00. The operational basis relies on the development of cancer vaccines and patent protection. Furthermore, the development of drugs within protected US clusters completely offsets the impact of global trade conflicts.

tuhurabio.com (HURA): Revenue and Sales Volume from 07/04/2022 to 11/18/2026

Analytical breakdowns for TuHURA Biosciences, Inc.

- market price and analyst price targets:
Summary company analysis:HURA, TuHURA
Core merchandise of TuHURA Biosciences, Inc.

For TuHURA Biosciences, Inc. (HURA), which is developing an oncology pipeline, sales reflect the current commercial demand for its developments. This metric accumulates daily cash flow from product sales, measuring real market demand. Analyzing the company's gross sales volume allows for the identification of a fundamental bottom and the forecasting of future revenues. The trend in the company's gross sales volume is critical when seeking strategic alliances and licensing. The stability of this indicator confirms the resilience of the business model.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue